Last reviewed · How we verify
5ARI
5-alpha-reductase inhibitor
5-alpha-reductase inhibitor Used for Benign prostatic hyperplasia, Androgenetic alopecia.
At a glance
| Generic name | 5ARI |
|---|---|
| Also known as | Proscar® (finasteride), Avodart® (dutasteride), Avodart® is a registered trademark of GlaxoSmithKline, Proscar® is a registered trademark of Merck |
| Sponsor | GlaxoSmithKline |
| Drug class | 5-alpha-reductase inhibitor |
| Target | 5-alpha-reductase |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 2 |
Mechanism of action
5-alpha-reductase inhibitors block the enzyme 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT), a hormone involved in the development of benign prostatic hyperplasia (BPH) and androgenetic alopecia.
Approved indications
- Benign prostatic hyperplasia
- Androgenetic alopecia
Common side effects
- Erectile dysfunction
- Decreased libido
- Breast tenderness
Key clinical trials
- 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy (NA)
- 5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression
- Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) (PHASE4)
- Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
- Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
- Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
- Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
- Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5ARI CI brief — competitive landscape report
- 5ARI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI